Earnings news, especially from Apple, could stir up a market that's waiting for the Fed.
U.S. sovereign bonds traded higher on Monday ahead of the Federal Reserve's two-day policy meeting this week and a raft of major corporate earnings.
The "Halftime Report" traders give their top trades of the show.
U.S. stock index futures indicated a flat to mildly lower open as traders prepare for the Fed's two-day meeting this week and a slew of earnings.
“Mad Money” host Jim Cramer takes the time to reveal the stocks that are running away from the competition.
Jim Cramer cannot believe what a stellar week of earnings this was. Now that the bar is set so high, he warned that Apple could get hurt next week.
Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.
Voter initiatives in California and Ohio to control prescription med prices have ramifications for the presidential contest.
The "Fast Money" traders give their final thoughts of the day.
The "Fast Money" traders look at the areas you should be watching going into the new week.
Jim Cramer gives his take quickly on caller favorite stocks, including this stock that is a great pick for young investors.
CNBC Contributor Mike Khouw describes bullish options activity in Bristol-Myers Squibb.
The "Fast Money" traders discuss what's on their radar.
CNBC "Halftime Report" trader Jon Najarian bought shares of Bristol Myers after spotting unusual activity in the options market.
Experienced investors use China-driven market selloffs to buy these quality companies.
Some of the names on the move ahead of the open.
Jim Cramer has had enough complaining! Instead of worrying about the market downturn, he lists the stocks that should be bought.
Despite some shakiness in the last month, the biotech sector offers some buying opportunities, "Fast Money" traders said.
The “Mad Money” host Jim Cramer gives his take on Apple’s recent decline.
Jim Cramer went back to the drawing board and presented his research on the rare biotechs that stumped him last month.